severity (16) . The aim of this study was to identify factors associated with frequent severe exacerbations of COPD that require hospitalization.
Materials and methods

Study subjects
In this retrospective case-control study we examined the risk factors and frequency of severe exacerbations in COPD patients that were hospitalized due to index exacerbation of COPD in the tertiary care university hospital Clinical Center of Kragujevac during a 3-year period (2010) (2011) (2012) . A total of 512 individual medical records were reviewed representing all hospitalized patients with COPD during the study period. We analyzed both female and male patients above 18 years old with established diagnosis of COPD, and 174 patients fulfilled these criteria and were included in further analysis. A group of 64 subjects who were frequent exacerbators formed the study population while 110 patients were in the control group. The remaining patients were excluded from the study due to incomplete patient files and several conditions that reduce lung function: associated restrictive disorders (interstitial fibrosis, tuberculosis, etc.), a history of lung cancer, previous lung surgery, recent myocardial infarction, or pulmonary embolism, as described elsewhere (2) . For the purposes of this study, respiratory comorbidities were defined as acute or chronic, partial or global respiratory failure.
The study protocol was approved by the ethical board of the Clinical Center of Kragujevac.
COPD exacerbations
COPD exacerbation was defined by the criteria of the GOLD guidelines (1) . We analyzed only severe exacerbations that required hospitalization.
Statistical analysis
Baseline demographic characteristics of the patients were described by means ± SD for continuous variables and frequency (percentages) for categorical variables. In order to determine differences in the mean values of continuous variables with normal distribution of values, the parametric Student t-test was used, and its nonparametric alternative, the Mann-Whitney test, was used if data did not follow a normal distribution. Differences between groups in the incidence of certain categories were determined by chi-square test or the Fisher test of real likelihood for low frequencies. Potential predictors of the observed outcome were determined using binary logistic regression, and values of the crude and adjusted odds ratios with corresponding confidence intervals of 95% were used to express the strength of correlations. All data were analyzed using SPSS 20 where P < 0.05 was considered statistically significant.
Results
This case-control study was conducted on 174 patients divided into two groups. The difference in age and mean level of BMI between the groups was statistically significant (P = 0.005, P = 0.018). Patients who had at least two exacerbations during the study period stayed longer in the hospital (P = 0.001) and had lower values of lung function parameters (FEV1 predicted %, FEV1/FVC ratio: P < 0.001, P = 0.001). A value of FEV1 of <50% was also more often noted in the group of frequent exacerbators (P = 0.007). Respiratory comorbidity rates were different between the groups (P = 0.014). Furthermore, patients in the control group had higher serum levels of CRP (P = 0.005) and higher frequency of CRP level above 10 mg/L (P = 0.012). We also found differences in the erythrocyte count (P = 0.008) and the rate of prescribing preventive therapy (P = 0.047). Baseline demographic characteristics of the patients are shown in Table 1 .
These baseline assessments were used as a starting point to analyze factors associated with frequent exacerbators. The best potential predictors of future exacerbations were age, length of hospital stay, FEV1 level, FEV1 <50%, FVC, FEV1/FVC ratio, respiratory comorbidities, frequency of CRP level above 10 mg/L, number of erythrocytes, and percentage of prescribed preventive therapy. Other results of univariate logistic regression are shown in Table 2 .
Factors that were associated with frequent exacerbators were assessed by a stepwise multivariate regression model. Results of this analysis revealed five independent predictors of frequent exacerbations: age, length of hospital stay, FEV1/FVC ratio, CRP level above 10 mg/L, and respiratory comorbidities (Table 3 ).
Discussion
The results from our study have shown that the patients under 65 years with the presence of respiratory comorbidities, longer hospital stay, lower FEV1/FVC ratio, and CRP <10 mg/L are more prone to experience a minimum of one additional hospitalization in the following year. Several studies have shown the association of a range of variables with frequency of different COPD exacerbations (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) .
We have noticed that age is associated with future exacerbations. Interestingly, it seems that older patients are less prone to experiencing at least two exacerbations in a year, which is inconsistent with a number of previous reports. Some studies failed to explain the influence of age on COPD exacerbations. Previous data showed that an increase in age of 10 years could produce about 3.5% increase in exacerbation rate in the following year (17) . Older patients (11, 18 ) and the patients above 65 years of age also had greater risk for repeated hospitalizations (19, 20) . Reexacerbation in 90 days was shown to be associated with age (21) . On the contrary, other authors observed high readmission rates for patients younger than 65 years (22), or did not suggest that age could be a predictor variable (15) . Our results showed that in the population of patients less than 65 years of age (n = 69) in both studied groups, 48 patients (69.9%) had respiratory comorbidities present. Further, out of this number, 27 patients (84.4%) were in the case group compared to 21 (56.8%) in the control group of patients, showing a significant difference (P = 0.013) (data not shown). This finding indicates that patients under 65 years with respiratory comorbidities have more chance of experiencing a minimum of two hospitalizations in a year. In our circumstances, patients also do not often adhere to prescribed therapy due to poor socioeconomic status and scant health education. Limited knowledge often increases fear for health. It is possible that older patients from our study used preventive therapy prescribed during the index hospitalization (long-acting bronchodilatorsLABAs, LAMA, theophylline, and inhaled steroids), more often due to more pronounced fear for their own health. Nevertheless, our multivariate analysis did not show a predictive value of prescribed preventive therapy, although its efficacy for prevention of acute exacerbations has been well established (17, 23, 24) . Treatment with inhaled LABAs and ICS decreased exacerbation frequency in a population of COPD patients older than 70 years (21) . In our study, preventive therapy was prescribed more often to the frequent exacerbators group, which is a younger group of patients and less adherent to prescribed medication. This finding could contribute to confounding since we had limited information about compliance. Similar observations have been presented previously (2) . Further examinations are needed to confirm this claim.
Higher exacerbation frequency is more likely to be reported in patients with longer length of hospital stay (LOH) according to our results. Prolonged time spent in the hospital due to COPD exacerbation may indicate more fragile patients with comorbidities like respiratory disease, heart failure, or diabetes (25) (26) (27) , who are more susceptible to exacerbations. Thus, these patients could more often experience at least two exacerbations in a year. Similar findings have been reported earlier (28, 29) , suggesting that ischemic heart disease might contribute to treatment failure, while elevated blood sugar level might support the growth of pathogens in the airway, promote inflammation, and increase the frequency of exacerbations (29) . At the same time, in our study, cardiovascular comorbidities and glucose level were not associated with frequent exacerbations. Other authors have outlined the same conclusion as we noticed regarding LOH, despite the fact that their basic results were the opposite: shorter LOH was associated with repeated hospitalization (25) . As suggested before, prolonged LOH is associated with disease severity (25, 29) , which is aligned with our findings showing that patients with more exacerbations had more severe forms of COPD, additionally aggravated by respiratory comorbidities (as shown in Table 1 ). Furthermore, these comorbidities may impair lung function additionally, disturb the overall health status, and limit the patient's ability to cope with acute illness and therefore increase the susceptibility to repeated hospitalization (25, 29) . Respiratory comorbidities were more often reported among the cases in our study. Their association with frequent exacerbations was also confirmed after adjustment (as shown in Table 3 ). Impairment of lung function as well as treatment response has been well established as a risk factor for frequent exacerbations (6, 8, 13, 30) , which is not in (30) . We found no association between FEV1 predicted, FEV1 <50% (GOLD staging III and IV), and exacerbation frequency in multivariate regression, although both variables showed significance in univariate analysis. Our study is not the only one that reported a lack of relationship between decreased lung function and exacerbation frequency (2, 25, 31) . Explanations proposed earlier suggest that this finding may be due to relatively small variations in FEV1 in the studied population of 43 ± 16 (25) and the spirometry testing being performed during hospitalization, not in a stable form of the disease (31) . Similar variations in FEV1 values measured during hospitalization were noticed in our study: 36.5 ± 14.3 and 45.4 ± 15.5 (as shown in Table 1 ). Our results indicated that the FEV1/FVC ratio might be a better predictor of future events during the course of COPD. Similar, the exacerbation onset in the next 6 months is associated with lower FEV1/FVC ratios (32) . Recent observations showed univariate association of similar parameters, FEV1 % predicted and FEV1/FVC, with frequent exacerbations that were lost in multivariate analysis for both variables (16), while others found no difference in FEV1 % predicted and FEV1/IVC between groups (33). Many guidelines suggest the FEV1/FVC ratio for assessment of the airway obstruction. However, interpretation of this test could be challenging since it depends not only on the degree of airflow limitation estimated based on the value of FEV1, which was significant lower in the case group of patients in our study, but it also depends on the value of FVC. Since FVC represent a volume of exhaled air, its value is strongly influenced by duration of expiratory time.
It was established that the longer the expiratory time is, the higher the value of FVC, and vice versa (34) . Patients with airflow obstruction find it difficult to empty their lungs and hence need more time for exhalation, as do older patients. In our study, the case group of patients had significantly lower levels of FEV1, FVC, and FEV1/FVC ratio. This result suggests that expiratory flow was slower in the control group of patients since they had significantly higher FVC values (as shown in Table 1 ). During air exhalation, expiratory muscles are activated and therefore patients could get tired during spirometry testing, which is more frequent in patients with obstruction but also in older patients. This could explain the significant difference in FVC values in favor of the control group, which was a significantly older group (as shown in Table  1 ). However, valid expiration during spirometry testing is considered to be one lasting at least 6 s (35), suggesting that our hypothesis could be confirmed or invalidated by assessing values of FEV6 measurements, which is a more stable indicator of expiration accuracy (36) independently related to annual lung function decline (37) and eliminates the potential age factor in interpretation of FVC values. Further studies are needed to investigate this issue. It would also be useful to determine the cut-off values of the FEV1/FVC ratio, which could be helpful in anticipating the course of COPD. Our results suggested that younger patients suffering from COPD with lower FEV1, FVC, and FEV1/FVC ratio have more chance of having at least two hospitalizations in a year. Interestingly, we found a significant difference in CRP levels in favor of the control group. Correlation between serum CRP levels and clinical parameters is still under discussion and the conclusions are not definitive. It was noticed that CRP level correlates with degree of pulmonary inflammation during the stable phase of COPD and could have a predictive value in the COPD course (38) , with increased incidences of hospitalization due to COPD in individuals with higher levels of CRP (39, 40) . (38) . Concentration of CRP is expected to be higher in frequent exacerbator groups of patients due to the enhanced inflammatory response (40) . It was reported that CRP is the most variable biomarker among several potential biomarkers in COPD (46) . Accordingly, it is possible that these variations of CRP concentration between the stable phase of COPD and exacerbation are more pronounced in the control group of patients. This group of patients could have less enhanced inflammatory response and thus less elevated CRP concentration during the stable phase of COPD, but during exacerbations, the control group of patients could have a greater increase of CRP concentration and more elevated values of this parameter than the case group of patients. Since they were an older group of patients with possible impairment of the immune system, and since CRP levels can predict bacterial exacerbation in patients with COPD (39), it is possible that bacterial infection was more often present in the control group of patients, causing a greater increase of CRP. This more intensive inflammatory response during exacerbation could somehow help with eradication of microorganisms and postpone the next exacerbation.
We are aware of several limitations of our study. First, since bronchodilator testing was conducted for only a small number of patients, we used prebronchodilator values instead, which is in contrast to guideline recommendations (1) . It remains unclear how this would affect the outcomes. Second, the case-control approach predisposes the present study to recall bias. Finally, the number of patients' medical files that we included in the study could be perceived as modest and may not represent the COPD population at large.
Despite these limitations, our study suggests that age, length of hospital stay, FEV1/FVC ratio, CRP level, and the presence of respiratory comorbidities could be used to anticipate future exacerbations requiring hospitalization of COPD patients. Adherence to prescribed therapy also influences the course of COPD. Concentration of CRP has predictive value for COPD exacerbation rates and should be measured during both the stable form of COPD and also during exacerbation. Learning to recognize, adjust, diminish, or eliminate these and a number of other risk factors may improve patient quality of life and help them to spend less time in hospital environments. Further prospective studies are necessary to resolve the significance of all potential predictors of the COPD exacerbation rate.
